卡铂
医学
紫杉烷
培美曲塞
内科学
肿瘤科
养生
安慰剂
彭布罗利珠单抗
肺癌
紫杉醇
化疗
非小细胞肺癌
癌症
顺铂
免疫疗法
乳腺癌
病理
替代医学
A549电池
作者
M. Calamia,R. Geller,P. Walden,K. MacDonald,I. Abraham
标识
DOI:10.1016/j.jtho.2022.09.078
摘要
The CHOICE-01 phase 3 randomized trial in previously untreated advanced non-small cell lung cancer (NSCLC) compared toripalimab or placebo plus chemotherapy (nab-paclitaxel+carboplatin [nPC] in squamous [s] and pemetrexed+platinum in non-squamous NSCLC). Toripalimab+chemo significantly improved PFS compared to placebo+chemo (8.3 vs 5.6 months; HR=0.58, 95%CI=0.442-0.769). In the KEYNOTE-407 phase 3 randomized trial in previously untreated metastatic sNSCLC, pembroluzimab+taxane+carboplatin showed significant improvement of PFS compared to placebo+taxane+carboplatin (8.0 vs 5.1 months; HR 0.57, 95%CI=0.47-0.69). We conducted a budget impact analysis of adding the toripalimab+nPC (T+nPC) regimen to the treatment mix in sNSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI